PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 2112559
PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 2112559
The global brain monitoring market was valued at USD 7.1 billion in 2025 and is projected to reach USD 11.6 billion by 2032, growing at a CAGR of 7.3% between 2026 and 2032. Growth is being driven by the rising number of people with neurological disorders worldwide, as there are more than 600 recognized neurological diseases according to the U.S. National Library of Medicine.
The disease burden is substantial. Neurological conditions affect over 3 billion people globally, with the overall burden increasing by around 18% since 1990, according to the World Health Organization, translating directly into higher institutional demand for EEG devices and intracranial pressure monitors.
Growing use of brain monitoring in intensive care units for traumatic brain injury and stroke patients is significantly supporting growth, alongside rising neurosurgical procedures that drive adoption of intraoperative monitoring technologies.
Key Insights
The Device category holds the larger product share, at 70%, including MRI, CT, and EEG systems; traumatic brain injuries resulted in approximately 214,110 TBI-related hospitalizations in 2020, according to the CDC. Accessories post the higher CAGR, at approximately 7.5%, driven by recurring demand for electrodes, sensors, and caps.
Traumatic Brain Injury is the largest application at 35% share; traumatic brain injuries contribute to approximately 69 million cases globally each year, according to the WHO. Dementia posts the highest CAGR, at approximately 7.8%; global dementia prevalence increased approximately 160.8% between 1990 and 2021.
Hospitals hold the largest end-user share, at 45%, given their concentration of neurodiagnostic infrastructure. Ambulatory Surgery Centers & Clinics post the highest CAGR, at approximately 7.7%, driven by CMS reimbursement support accelerating the shift toward outpatient neurological diagnostics.
North America holds the largest regional share, at 40%, driven by rising neurological disease incidence and advanced diagnostic technology adoption. More than 6.9 million Americans aged 65 and older are living with Alzheimer's disease, according to the Alzheimer's Association.
The U.S. is the largest country market, supported by a high concentration of neurocritical care units; the CDC reported over 69,000 traumatic brain injury-related deaths in 2021, equivalent to approximately 190 deaths per day.
Asia-Pacific posts the highest regional CAGR, at approximately 8.2%, driven by China, India, Japan, and South Korea advancing along complementary healthcare development trajectories. China's research and development expenditure exceeded 3.6 trillion yuan in recent years, according to the National Bureau of Statistics of China.
India's National Health Mission has expanded primary healthcare services, with over 1.7 lakh Ayushman Arogya Mandirs improving access to diagnostic and primary care.
AI integration and non-invasive device innovation are a defining trend, as dry electrode systems and in-ear EEG devices extend continuous monitoring beyond clinical laboratories. Cleveland Clinic and other institutions are actively testing AI-powered EEG interpretation systems capable of analyzing large volumes of brainwave data within seconds.
Rising global neurological disease burden remains the biggest driver, as aging populations and rising cardiovascular risk factors increase stroke and vascular dementia incidence. The WHO identifies neurological disorders as the leading cause of disability globally, while fewer than one in three countries have a national policy addressing these conditions.
High device costs and neurologist workforce scarcity are the main restraint. Low-income countries have more than 80 times fewer neurologists per capita compared to high-income nations, according to the WHO, creating a structural mismatch between technology availability and clinical expertise.
Aging demographics and underserved home-care settings present a clear opportunity. Dementia affects approximately 55 million people worldwide, projected to reach 139 million by 2050, according to the WHO, while epilepsy affects approximately 50 million people globally requiring long-term monitoring.
The competitive landscape remains semi-consolidated, with multinational companies including Medtronic, GE HealthCare, Koninklijke Philips, and Siemens Healthineers holding significant share in high-value imaging alongside numerous specialized mid-sized firms. Recent activity includes Natus Medical's May 2025 launch of BrainWatch, a point-of-care EEG solution for critical care settings, and Nihon Kohden's November 2024 acquisition of a majority stake in NeuroAdvanced Corp., strengthening its epilepsy diagnostics capabilities through Ad-Tech's intracranial electrode portfolio.